Results 71 to 80 of about 8,261 (192)
, 2022 Objective: There is a need for the immunogenicity of different boosters after widely used inactivated vaccine regimens. We aimed to determine the effects of BNT162b2 and CoronaVac boosters on the humoral and cellular immunity of individuals who had two doses of CoronaVac vaccination. Methods: The study was conducted in three centers (
Füsun Can +12 more
openaire +1 more source
Vaccines, 2023 To compare immunogenicity and reactogenicity of five COVID-19 vaccine regimens against wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a prospective cohort study was conducted among healthy participants aged ≥18 years who had ...
Tavitiya Sudjaritruk +12 more
doaj +1 more source
Viruses, 2022 We evaluated neutralizing antibodies against the Omicron variant and Anti-Spike IgG response in solid organ (SOT) or hematopoietic stem cell (HSTC) recipients after a third dose of BNT162b2 (BNT) or CoronaVac (CV) following two doses of CV. In total, 95 participants underwent SOT (n = 62; 44 liver, 18 kidney) or HSCT (n = 27; 5 allogeneic, 22 ...
Çiğdem Erol +20 more
openaire +4 more sources
Emerging Microbes and Infections, 2023 Severe COVID-19 appears to be disproportionately more common in children and adolescents since the emergence of Omicron. More evidence regarding vaccine effectiveness (VE) is urgently needed to assist policymakers in making decisions and minimize vaccine
Vincent Ka Chun Yan +11 more
doaj +1 more source
Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2
Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.SARS‐CoV‐2 vaccine induces cellular immune response. T‐cells play a protective role for COVID‐19. ABSTRACT The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have
Valentina Tovar +4 more
wiley +1 more source
CoronaVac efficacy data from Turkey [PDF]
The Lancet, 2021 Durusu Tanrıöver, Mine +3 more
openaire +3 more sources
Allergy, 2022 AbstractBackgroundIt is essential to know about immune response levels after booster doses of the two different types of vaccines, mRNA, and the inactivated, currently used against COVID‐19. For this purpose, we aimed to determine the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the humoral and cellular immunity of individuals who had two ...
Zeynep Ece Kuloğlu +12 more
openaire +2 more sources
Journal of Medical Virology, Volume 98, Issue 3, March 2026.ABSTRACT Complement temporal activation kinetics, activation pathways, and their relationship with thromboinflammation and antibody responses in severe vaccination‐COVID‐19 remains unclear. Based on a vaccinated‐infected cohort, we analyzed complement immune responses across mild to critical COVID‐19 cases by a dynamic model.
Jinpeng Cao +16 more
wiley +1 more source
, 2022 The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of
Chua, Jia Xin +7 more
core +1 more source
Evaluation and follow-up of antibody formation after CoronaVac vaccine
Revista da Associação Médica Brasileira, 2022 The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine.The study group (n=65) were between 21 and 60 years old and received two doses of the CoronaVac vaccine.
Büşra Çalişir +6 more
openaire +5 more sources